Drug Type Antibody |
Synonyms BB 208, BB208 |
Target |
Action inhibitors, antagonists |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Tumor-associated antigen inhibitors(Tumor-associated antigen inhibitors) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pancreatic Cancer | Preclinical | United States | 15 May 2024 |






